###### Key messages

-   A low multibiomarker disease activity (MBDA) score at baseline was associated with a very low risk of radiographic progression (RP).

-   Achievement of a low MBDA score at later time-points also was associated with low risk of RP.

-   Among patients with low C reactive protein or erythrocyte sedimentation rate, the majority had high/moderate MBDA score and a substantial proportion had RP.

-   Combination of MBDA score at multiple time-points may help choose optimal therapy, since patients with a high MBDA score might be better protected from RP while using biologics compared with patients having a low/moderate MBDA score.

Introduction {#s1}
============

In rheumatoid arthritis (RA), early therapeutic intervention increases the chances of achieving better clinical and radiographic outcomes.[@R1] [@R2] However, radiographic progression (RP) is not always associated with clinically severe signs and symptoms.[@R3] Early identification of patients at a risk for RP would be beneficial for the optimal therapy choice leading to prevention of RP.

There are several factors reported to be independent predictors of RP, including biomarkers (anticyclic citrullinated peptide (anti-CCP) autoantibody status, erythrocyte sedimentation rate (ESR), C reactive protein (CRP)), radiographic destruction at baseline (BL) (bone erosions and joint space narrowing) and smoking status.[@R8]

The multibiomarker disease activity (MBDA) score (Vectra DA) is an RA disease activity measure based on serum concentrations of 12 protein biomarkers.[@R20] [@R21] In established RA, limited RP has been reported among patients in remission according to the MBDA score, while those with high (\>44) MBDA score, despite being in remission according to the disease activity score of 28 joints based on CRP (DAS28-CRP) or to the American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) criteria, were found to be at significantly higher risk.[@R22]

Using data from the Swedish Farmacotherapy (SWEFOT) clinical trial[@R23] [@R24] of early RA (eRA), we have previously shown that BL MBDA score, taken before the initiation of disease-modifying anti-rheumatic drugs (DMARDs), could define patients who were at very low versus higher risk of rapid RP (RRP) during 1 year of follow-up.[@R25] However, patients for whom screening with biomarkers is of interest are not necessarily DMARD naïve.

Thus, we further studied the MBDA score, CRP, ESR and DAS28 at multiple time-points in a subset of patients from the SWEFOT trial, to evaluate these measures as predictors of high versus low risk of subsequent RRP in RA patients.

Methods {#s2}
=======

Study population {#s2a}
----------------

Overall, 487 patients with eRA were recruited to the SWEFOT trial,[@R23] with age ≥18 years, symptom duration \<1 year and DAS28\>3.2. After 3 months of methotrexate (MTX) monotherapy, responders (DAS28≤3.2) continued the treatment and non-responders (DAS28\>3.2) were randomly assigned to receive (1) non-biological (MTX+sulfasalazine (SSZ)+hydroxychloroquine (HCQ)) DMARD triple therapy (TT) or (2) in addition to MTX, biological (antitumour necrosis factor (anti-TNF): infliximab) therapy. The analyses of RP from BL to year 1 and to year 2 for this study were performed on a subset of 220 patients with eRA for whom the MBDA scores, CRP, ESR and DAS28 were available at BL. Of the 220 patients, data on these four disease activity measures at month 3 and year 1 were available for 205 and 133 patients, respectively. From the study subset, 76 patients responded to MTX monotherapy and 144 were randomised to the TT (n=73) or anti-TNF (n=71) treatment arms. The SWEFOT study was approved by regional ethics committees of all participating units.

Disease outcomes {#s2b}
----------------

The categorisation of disease activity at BL, month 3 and year 1 by DAS28 and CRP, was as follows: for DAS28, EULAR cut-offs were used---low ≤3.2, moderate \>3.2--5.1 and high \>5.1[@R26]; for CRP, low ≤10 mg/L, moderate \>10--30 mg/L and high \>30 mg/L.[@R27] As there is no defined threshold value for categorisation of disease activity according to ESR, tertiles at BL were used: low ≤26 mm/h, moderate 27--45 mm/h and high \>45 mm/h. The modified Sharp/van der Heijde scores (SHSs)[@R28] from radiographs of hands and feet were evaluated (by 2 certified assessors) at BL, year 1 and year 2, and patients with an increase of the SHS at any subsequent time-point by \>5 (ΔSHS\>5) were considered as RRP.[@R29] [@R30] In addition, we analysed a threshold defined for clinically relevant RP (CRRP, (ΔSHS\>3)).[@R31]

Biomarker measurement and the MBDA score {#s2c}
----------------------------------------

The biomarkers were measured by Crescendo Bioscience (South San Francisco, California, USA). The following 12 biomarkers were used for calculation of the MBDA score: vascular cell adhesion molecule 1, epidermal growth factor, vascular endothelial growth factor, interleukin 6, TNF receptor 1, matrix metalloproteinases 1 and 3, cartilage glycoprotein 39 (YKL-40), leptin, resistin, serum amyloid A and CRP. The biomarkers were measured by electrochemiluminescence-based multiplex immunoassay on the Meso Scale Discovery Multi-Array platform.[@R32] The MBDA score was calculated using the Vectra DA algorithm; it has a scale from 1 (lowest disease activity) to 100 (highest disease activity). Threshold values of MBDA score grouped patients into three disease activity categories: low \<30, moderate 30--44 and high \>44.[@R21] [@R22]

Statistical analyses {#s2d}
--------------------

BL characteristics and demographic data were analysed by descriptive statistics. The comparison of these data between RRP and non-progressors was carried out using the Mann-Whitney U test. Proportions of patients with RRP between the TT and anti-TNF therapy arms (among MTX non-responders) as well as among patients with low, moderate or high disease activity categories, were evaluated by χ^2^ test or, in case of limited sample size, Fisher\'s Exact test. The ΔSHS values among patients with low, moderate or high disease activity categories according to MBDA score, CRP and DAS28, were compared using the Kruskal-Wallis test. The data were analysed using IBM SPSS Statistics software V.22.

Results {#s3}
=======

BL characteristics {#s3a}
------------------

BL characteristics and demographic data of the 220 patient subset with available samples for biomarker analyses were similar to the whole SWEFOT cohort ([table 1](#RMDOPEN2015000197TB1){ref-type="table"}). As expected from our previous studies on predictors of RP, ESR, CRP and MBDA, scores were significantly higher at BL in patients with RRP at year 1 versus those without RRP, whereas no significant difference was detected regarding DAS28 ([table 1](#RMDOPEN2015000197TB1){ref-type="table"} and [figure 1](#RMDOPEN2015000197F1){ref-type="fig"}), Clinical Disease Activity Index (CDAI) or Simplified Disease Activity Index (SDAI) ([figure 1](#RMDOPEN2015000197F1){ref-type="fig"}). Similar results were found based on 2-year radiographic data (results not shown).

###### 

Baseline characteristics and demographic data of patients from the SWEFOT trial

                                                                                         Subset of patients with radiographs and clinical measures at baseline and 1 year                               
  ------------------------------------------------------------------------ ------------- ---------------------------------------------------------------------------------- ------------- ------------- -------
  Female: N (%)                                                            344 (70)      156 (71)                                                                           30 (73)       126 (70)      0.724
  Symptom duration (months)                                                6.2 (4.6)     5.9 (3.2)                                                                          6.5 (3.6)     5.7 (3.1)     0.249
  Anti-CCP status: N (%)                                                                                                                                                                                0.073
   Positive                                                                275 (57)      126 (57)                                                                           29 (71)       97 (54)       
   Negative                                                                157 (32)      84 (38)                                                                            11 (27)       73 (41)       
   Not available                                                           55 (11)       10 (5)                                                                             1 (2)         9 (5)         
  RF status: N (%)                                                                                                                                                                                      0.118
   Positive                                                                330 (68)      142 (65)                                                                           31 (76)       111 (62)      
   Negative                                                                152 (31)      76 (34)                                                                            10 (24)       66 (37)       
   Not available                                                           5 (1)         2 (1)                                                                              0 (0)         2 (1)         
  28 Swollen joint count                                                   10.8 (5.3)    10.8 (5.4)                                                                         10.0 (5.4)    10.7 (5.4)    0.809
  28 Tender joint count                                                    9.6 (6.1)     9.3 (5.9)                                                                          8.8 (5.2)     9.5 (6.0)     0.775
  ESR (mm/h)                                                               39.9 (25.9)   41.2 (26.9)                                                                        52.6 (33.5)   38.5 (24.5)   0.028
  CRP level (mg/L)                                                         33.8 (36.8)   34.5 (36.9)                                                                        46.2 (43.7)   31.8 (34.7)   0.049
  Patient\'s Global Assessment of Disease Activity (VAS 0--100 mm) score   56 (23.9)     55.8 (24.8)                                                                        63.4 (21.0)   54.1 (25.3)   0.053
  DAS28                                                                    5.7 (1.0)     5.7 (1.0)                                                                          5.9 (1.2)     5.7 (1.0)     0.136
  MBDA score                                                               58.6 (15.1)   59.3 (14.7)                                                                        66.7 (12.3)   57.6 (14.8)   0.001
  SHS mean (median)                                                        4.5 (2)       4.9 (2)                                                                            6.8 (3)       4.5 (1)       0.039

\*Number of missing patients for 'All patients' column: 28 swollen and tender joint count (n=2), ESR (n=5), CRP and Patient\'s Global Assessment (n=3), DAS28 (n=8), MBDA (n=185) and SHS (n=57).

anti-CCP, anticyclic citrullinated peptide; CRP, C reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; MBDA, multibiomarker disease activity; RF, rheumatoid factor; SHS, Sharp/van der Heijde score; VAS, visual analogue scale.

![Distribution of disease activity measures among radiographic progressors (Δ Sharp/van der Heijde score (ΔSHS) \>5) and non-progressors (ΔSHS≤5). Multibiomarker disease activity (MBDA) score, C reactive protein (CRP), erythrocyte sedimentation rate (ESR), disease activity score of 28 joints (DAS28), Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) at baseline among patients with radiographic progression (grey boxes) and without progression (white boxes) from baseline to year 1.](rmdopen2015000197f01){#RMDOPEN2015000197F1}

Relationship of disease activity categories at different time-points with frequency of RRP {#s3b}
------------------------------------------------------------------------------------------

Proportions of patients with subsequent RRP (BL--year 2 and year 1--2) were compared among patients with low, moderate or high disease activity according to the MBDA score, CRP, ESR or DAS28 at month 3 or year 1 ([figure 2](#RMDOPEN2015000197F2){ref-type="fig"}). The categorisation of patients by MBDA score, CRP and ESR at month 3 showed a significant difference in the proportion of RRP during 2-year follow-up (p=0.002, p=0.003 and p=0.002, respectively; [figure 2](#RMDOPEN2015000197F2){ref-type="fig"}A); while the same was not true for DAS28 (p=0.333). When assessed at year 1, all these four disease activity markers showed a significantly different proportion of patients with subsequent RRP from year 1 to 2 (p\<0.001, p=0.008, p=0.004 and p=0.005, respectively; [figure 2](#RMDOPEN2015000197F2){ref-type="fig"}B). The categories of the MBDA score showed similar results when ΔSHS\>3 cut-off was used for CRRP (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S1).
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![Proportion of radiographic progressors in patients with rheumatoid arthritis during 2 years follow-up according to categories of multibiomarker disease activity (MBDA) score, C reactive protein (CRP), erythrocyte sedimentation rate (ESR) and disease activity score of 28 joints (DAS28) at multiple time-points. The proportion of radiographic progression (RP) (A) at year 2 in patients whose 3-month categories of MBDA score are cross classified versus CRP, ESR and DAS28 at month 3 and (B) from year 1 to 2 in patients whose 1 year categories of MBDA score are cross-classified versus categories of CRP, ESR or DAS28 at year 1.](rmdopen2015000197f02){#RMDOPEN2015000197F2}

Relationship of disease activity categories at different time-points with the change of the SHS {#s3c}
-----------------------------------------------------------------------------------------------

The changes of SHS (ΔSHS) from BL to year 1 and to year 2 as well as from year 1 to 2 were compared among RA patients with low, moderate or high disease activity categories according to the MBDA score, CRP and DAS28 at month 3 (n=205) and year 1 (n=133; [table 2](#RMDOPEN2015000197TB2){ref-type="table"}). The ΔSHS was significantly different across low/moderate/high categories of the MBDA score and CRP, at month 3 and year 1, while no significant differences were observed across DAS28 categories ([table 2](#RMDOPEN2015000197TB2){ref-type="table"}A). When compared among patients within the same categories of different disease activity measures ([table 2](#RMDOPEN2015000197TB2){ref-type="table"}B), patients with a low MBDA score at month 3 had significantly lower ΔSHS from BL to year 1 (0.5) than those with low CRP (2.2) or low DAS28 (2.2), p=0.029, and significantly lower ΔSHS from BL to year 2 (1.5, 3.5 and 3.7, respectively; p=0.037). Patients with moderate MBDA score at year 1 had significantly lower ΔSHS (1.0) during the subsequent year than those with moderate CRP (4.1) or DAS28 (1.9); p=0.048. In the rest of the cases, patients with low or moderate MBDA scores at any time-point had numerically but not significantly lower ΔSHS during the subsequent year compared with those having a low or moderate CRP or DAS28. And there was no significant difference in ΔSHS among patients with a high MBDA score, CRP or DAS28 ([table 2](#RMDOPEN2015000197TB2){ref-type="table"}B).

###### 

The change of SHS from BL to year 1 and year 2, and from year 1 to 2, among early RA patients with low, moderate and high MBDA scores, CRP and DAS28 at multiple time-points

  Disease activity time-point   Time-period for ΔSHS   ΔSHS mean (median)                                                                                                                               
  ----------------------------- ---------------------- -------------------- -------------- ------------- ---------- ------------- ----------- ----------- ----------- ----------- ----------- --------- -------
  Month 3                       BL--year 1 (n=205)     0.5 (0)              2.4 (1)        4.8 (3)       \<0.001    2.2 (0)       4.0 (3)     8.2 (4.5)   0.004       2.2 (0.5)   2.7 (1)     5.1 (1)   0.417
                                BL--year 2 (n=205)     1.5 (0)              3.6 (2)        7.2 (4.5)     \<0.001    3.5 (1)       6.1 (4.5)   12.3 (6)    \<0.001     3.7 (1)     3.9 (2)     8.0 (3)   0.238
  Year 1                        Year 1--2 (n=133)      0.5 (0)              1.0 (0)        4.7 (3.0)     0.004      1.1 (0)       4.1 (2.5)   8.7 (3)     0.024       0.8 (0)     1.9 (0)     6.9 (3)   0.074
                                                                                                                                                                                                        
  **Panel (B)**                 **Low**                **p Value**          **Moderate**   **p Value**   **High**   **p Value**                                                                         
                                **MBDA**               **CRP**              **DAS28**      **MBDA**      **CRP**    **DAS28**     **MBDA**    **CRP**     **DAS28**                                     
                                                                                                                                                                                                        
  Month 3                       BL--year 1 (n=205)     0.5 (0)              2.2 (0)        2.2 (0.5)     0.029      2.4 (1)       4.0 (3)     2.7 (1)     0.665       4.8 (3)     8.2 (4.5)   5.1 (1)   0.199
                                BL--year 2 (n=205)     1.5 (0)              3.5 (1)        3.7 (1)       0.037      3.6 (2)       6.1 (4.5)   3.9 (2)     0.336       7.2 (4.5)   12.3 (6)    8.0 (3)   0.167
  Year 1                        Year 1--2 (n=133)      0.5 (0)              1.1 (0)        0.8 (0)       0.883      1.0 (0)       4.1 (2.5)   1.9 (0)     0.048       4.7 (3.0)   8.7 (3)     6.9 (3)   0.890

p Values defined by Kruskal-Wallis test.

BL, baseline; CRP, C reactive protein; DAS, disease activity score; MBDA, multibiomarker disease activity; RA, rheumatoid arthritis; SHS, Sharp/van der Heijde score.

Relation of the MBDA score categories with those of CRP and ESR, and RRP {#s3d}
------------------------------------------------------------------------

When stratified across low/moderate/high categories of CRP, ESR or DAS28, all 33 patients with a low MBDA scores at month 3 also had low CRP and low ESR, with the exception of 1 patient with moderate ESR, and 17 had low DAS28 ([figure 2](#RMDOPEN2015000197F2){ref-type="fig"}A). Of these 33 patients, only 3 had RRP at year 2. In contrast, among patients with low CRP, ESR or DAS28 at month 3, the majority had a moderate/high MBDA score, and 23%, 24% and 24% of them, respectively, had RRP at year 2 ([figure 2](#RMDOPEN2015000197F2){ref-type="fig"}A). Of these patients with RRP, only three had a low MBDA score. Among patients with a low MBDA score at year 1 (n=60), 1 had moderate CRP, 4 had moderate ESR, 20 had moderate DAS28 and 1 had high DAS28 ([figure 2](#RMDOPEN2015000197F2){ref-type="fig"}B). Of these 60 patients, only 2 (3%) had RRP from year 1 to 2. In contrast, among patients with low CRP (n=112), low ESR (n=101) or low DAS28 (n=66) at year 1, almost half had a moderate/high MBDA score, and of the 9% with low CRP who had RRP from year 1 to 2, only two patients had a low MBDA score.

Association of conversions in MBDA score categories with subsequent RRP {#s3e}
-----------------------------------------------------------------------

Changes of disease activity category (low, moderate and high) according to the MBDA scores, CRP or ESR from BL to month 3 or to year 1 were analysed versus subsequent RRP (from BL to year 1 and from year 1 to 2, respectively; [figure 3](#RMDOPEN2015000197F3){ref-type="fig"}). For the five patients with low MBDA scores at BL, all five remained low at month 3 ([figure 3](#RMDOPEN2015000197F3){ref-type="fig"}A, left bar graph), as did the four with available MBDA data at year 1 ([figure 3](#RMDOPEN2015000197F3){ref-type="fig"}B, left bar graph) and none had RRP over the 2 years of follow-up. Likewise, none of the patients who shifted from a moderate MBDA score at BL to low at month 3 or year 1 progressed radiographically during the subsequent 1 year. In contrast, the highest proportion of patients with RRP was detected among patients with a high MBDA score at BL that remained high at month 3 or year 1. Those whose MBDA scores had decreased from a high to a low category at month 3 or to low/moderate at year 1, had significantly lower frequencies of RRP compared with those whose MBDA score remained at high levels at these time-points ([figure 3](#RMDOPEN2015000197F3){ref-type="fig"}A, B left bar graphs). In contrast, patients who remained with low disease activity at month 3 or year 1 according to CRP or ESR ([figure 3](#RMDOPEN2015000197F3){ref-type="fig"}A, B, middle and right bar graphs, respectively) still had some occurrence of RRP. Patients who shifted to low CRP or ESR at month 3 or year 1 had a 3--24% risk of RRP over the subsequent year, with the exception of patients decreasing from moderate to low levels of ESR at year 1, who did not develop RRP over the following year ([figure 3](#RMDOPEN2015000197F3){ref-type="fig"}B, right bar graph).

![Association of radiographic progression with change in disease activity categories according to the MBDA score, CRP and ESR. Change in categories according to MBDA score, CRP or ESR (A) from BL to month 3 and radiographic progression from BL to year 1, and (B) from BL to year 1 and radiographic progression from year 1 to 2. BL, baseline; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; MBDA, multibiomarker disease activity; SHS, Sharp/van der Heijde score.](rmdopen2015000197f03){#RMDOPEN2015000197F3}

In general, when using the MBDA score at a single time-point, comparison of low/moderate versus high MBDA scores at BL and at year 1 was the most optimal grouping for discrimination of patients at low versus higher risk of RRP during the following year, whereas at month 3, low versus moderate/high grouping was better ([figure 3](#RMDOPEN2015000197F3){ref-type="fig"} and online [supplementary table](#SM2){ref-type="supplementary-material"} S1). When using the MBDA score at single time points for evaluation of RRP from BL to year 1, both BL and month 3 data were equally predictive for a subset at low risk of RRP. Of patients with a low/moderate MBDA score at BL (n=33) or with a low MBDA score at month 3 (n=33), only one had RRP at year 1. Combination of these two time-points, however, allowed an increase in sample size of the patients at low risk of RRP, that is, of the patients with a low/moderate MBDA score at BL, or those whose MBDA score dropped from high at BL to low at month 3 (n=50), only two patients had RRP at year 1 ([figure 3](#RMDOPEN2015000197F3){ref-type="fig"} and online [supplementary table](#SM2){ref-type="supplementary-material"} S1).
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###### 

Predictive capacity of the MBDA score at multiple time-points

Evaluation of the MBDA score at BL, month 3 and year 1 for prediction of RRP during the second year of follow-up (from year 1 to 2) revealed that the latest time-point (year 1) was the best single time-point for identification of a subgroup of patients at very low risk of RRP (5 of 87). Combination of two time-points (change of the MBDA categories from BL to year 1 or from month 3 to year 1) slightly increased the sample size of patients who were identified to be at very low risk of RRP. Thus, 5 of 90 patients who had a low/moderate MBDA score at BL or whose score decreased from high at BL to low/moderate at year 1, had RRP. When considering change of the MBDA categories from month 3 to year 1: 5 of 88 patients who had a low MBDA score at month 3 or decreased MBDA score from high (month 3) to low/moderate (year 1) or had persistent moderate MBDA score, had RRP from year 1 to 2 (see online [supplementary table](#SM2){ref-type="supplementary-material"} S1).

RRP in triple versus anti-TNF therapy arms and its relation to MBDA score categories {#s3f}
------------------------------------------------------------------------------------

In this study, patients categorised by the MBDA score (low, moderate and high) within each therapy group (TT, anti-TNF and MTX monotherapy) had similar patterns for the risk of RRP during the subsequent year as if looked at all therapy groups together (results not shown). As has been previously reported, in the SWEFOT trial, there was a significantly higher proportion of RRP over 2 years in the TT group as compared with patients randomised to anti-TNF therapy.[@R24] When considering MBDA score categories, the proportions of RRP in the MTX non-responders with a low/moderate MBDA score were not statistically significantly different between the TT and anti-TNF treatment arms ([figure 4](#RMDOPEN2015000197F4){ref-type="fig"}). However, patients with a high MBDA score at BL or month 3 had a significantly higher proportion of RRP at year 2 in the TT group, compared with the anti-TNF group (45% vs 25%, p=0.022 and 57% vs 32%, p=0.038, respectively; [figure 4](#RMDOPEN2015000197F4){ref-type="fig"}A, left and middle bar graphs); and a numerically but not significantly greater rate of RRP (year 1 to 2) in the triple versus anti-TNF-treated patients with a high MBDA score at year 1 ([figure 4](#RMDOPEN2015000197F4){ref-type="fig"}A, right bar graph). When using ΔSHS\>3 as a definition of CRRP, patients with high MBDA scores in the TT arm had a numerically higher proportion of CRRP than those in the anti-TNF therapy group ([figure 4](#RMDOPEN2015000197F4){ref-type="fig"}B). Patients with high CRP at BL, month 3 or year 1 did not differ significantly in proportion or RRP among TT and anti-TNF treated groups (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S2).

![Radiographic progression among three therapy groups (triple therapy group, anti-TNF treatment group and MTX responders) stratified by MBDA categories at multiple time-points. Proportion of patients with radiographic progression defined as (A) ΔSHS\>5 and (B) ΔSHS\>3. Left and middle bar graphs represent proportion of patients with 2-year radiographic progression stratified by the MBDA score at BL and month 3, respectively. Right bar graph shows radiographic progression from year 1 to 2 among patients stratified by the MBDA score at year 1. BL, baseline; MBDA, multibiomarker disease activity; MTX, methotrexate; NS, not significant; SHS, Sharp/van der Heijde score; TNF, tumour necrosis factor.](rmdopen2015000197f04){#RMDOPEN2015000197F4}

Discussion {#s4}
==========

In this study on patients with eRA who participated in the SWEFOT trial, the 12 serum biomarker-based MBDA score at BL, month 3 and year 1 was associated with the status of subsequent RRP. Thus, having a low MBDA score at BL, or a score reducing to a low level at any of the later time-points, was associated with a lower risk of subsequent RRP. Furthermore, numerically smaller proportions of RRP were observed among patients with a low MBDA score as compared with patients having low CRP, ESR or DAS28 at the respective time-points.

These results confirm and extend previously published findings. During development of the MBDA score, Centola *et al*[@R20] demonstrated (using data from multiple clinical cohorts) that scores based on those candidate biomarkers at BL and year 1 were correlated with subsequent change of SHS from BL to year 1 and from year 1 to 2, respectively. Van der Helm-van Mil *et al*[@R22] showed that patients in remission according to the MBDA score had a lower risk of RP, compared with those in remission according to DAS28-CRP or ACR/EULAR criteria. In contrast, Bakker *et al* could not show BL MBDA scores to significantly predict RP over 2 years in the CAMERA trial. After inclusion of rheumatoid factor and BL erosions in multivariate logistic regression analyses, however, the MBDA score at BL, but not DAS28-CRP, achieved borderline significance.[@R33]

In our previous study based on this trial, we demonstrated the independent predictive ability of the MBDA score at BL for subsequent 1 year RRP.[@R25] This result posed a question concerning the role of the MBDA score in patients with RA whose disease (and MBDA score) is already affected by treatment. Therefore, here we assessed the predictive capacity of the MBDA score at month 3 (patients on MTX monotherapy) for RRP from BL to year 1 and year 2, as well as at year 1 (MTX non-responders, either on TT or on anti-TNF therapy) as a predictor of RRP from year 1 to 2. DAS28, CRP and ESR were studied in parallel with the MBDA scores from each time-point.

In this study, the proportions of patients with RRP during the first and second years as well as the 1-year change in SHS from BL differed significantly between patients with low/moderate/high MBDA scores or CRP at month 3 or year 1 ([figure 2](#RMDOPEN2015000197F2){ref-type="fig"} and [table 2](#RMDOPEN2015000197TB2){ref-type="table"}). In order to elucidate the objectiveness of cut-off values for MBDA and CRP, the data on ΔSHS was plotted against MBDA score, CRP and ESR values (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S3). This figure illustrates that some patients at very low CRP levels at all three time-points have RRP over 2 years, while those with low or moderate MBDA scores have lower proportions with RRP. Moreover, when comparing proportions of patients with RRP from BL to year 2 between the TT and anti-TNF treated groups, patients with a high MBDA score at BL or month 3 differed significantly, whereas those with high CRP did not (see [figure 4](#RMDOPEN2015000197F4){ref-type="fig"} and online [supplementary figure](#SM1){ref-type="supplementary-material"}s S2). Although using ΔSHS\>3 cut-off did not show a significantly, but only numerically, higher proportion of patients with CRRP in the TT versus anti-TNF therapy group ([figure 4](#RMDOPEN2015000197F4){ref-type="fig"}B), when comparing all patients together, the associations of the MBDA score categories with risk of CRRP were similar to the association with RRP using ΔSHS\>5 cut-off (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S1).

When comparing predictive ability of the MBDA score at different time-points, we noticed that combination of the MBDA score from BL and month 3 substantially improved the identification of patients at a low risk of RRP during the first year of the trial compared with single time-points, due mainly to an increase in the sample size from n=33 to n=50 (see online [supplementary table](#SM1){ref-type="supplementary-material"} S1). As for the prediction of RRP during the second year of follow-up, year 1 was the best single time-point for identification of patients at a low risk of RRP. Simultaneous use of the MBDA score from BL and year 1 or from month 3 and year 1 slightly increased the sample size of this subset of patients (from 87, to 90 and 88, respectively).

One of the limitations of this study is that it was based on one cohort, which was not a full representation of the RA population. However, the SWEFOT trial was designed to include a real-life eRA population. Another limitation was that the MTX responder population lacked MBDA data at year 1, which limited our ability to perform analyses. Next, because of the lack of information about cut-offs for CRP and ESR categories, we had to use non-validated cut-offs for CRP and tertiles for ESR in order to define low/moderate/high levels of disease activity. This makes the comparison with MBDA score more limited and the health-economic point of view cannot be evaluated. Changes in the treatment of patients from different arms could affect the radiographic outcome. And, finally, in comparison of proportion of RRP within each therapy group, some subgroups of patients are very small. Considering this and the fact of multiple testing, the results of significant difference of proportions of RRP between TT and anti-TNF therapy groups need to be confirmed.

The strength of this study is the availability of data from multiple time-points, which provides a more comprehensive evaluation of the MBDA score as a predictor of RRP at the onset of the disease, and also during subsequent treatment. The presence of two different treatment strategies (TT vs biological therapy) gave an opportunity to study the MBDA score as a predictor of patients at high versus low risk of RRP for each therapy group, separately. As the data from [figure 4](#RMDOPEN2015000197F4){ref-type="fig"} suggest, patients with a high MBDA score would benefit more from anti-TNF therapy than from TT, decreasing their risk of RRP by year 2. Thus, while MBDA testing is more expensive than using conventional biomarkers (ie, ESR and CRP), targeting (biological) therapies to the patients with the greatest potential benefit may generate considerable savings.

In conclusion, a low MBDA score at BL, month 3 and year 1, was predictive for low risk of RRP over 2 years of follow-up in patients with eRA, and this association was stronger (non-significantly) than associations with low DAS28, CRP or ESR. The MBDA score may thereby become a useful tool for guiding treatment choices in individual patients.
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